Ingrid Delaet Sells 272 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 272 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total transaction of $37,563.20. Following the transaction, the insider now directly owns 2,507 shares in the company, valued at $346,216.70. The trade was a 9.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ingrid Delaet also recently made the following trade(s):

• On Tuesday, December 17th, Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $138.10 on Friday. The company’s fifty day moving average price is $128.11 and its 200-day moving average price is $130.81. The firm has a market capitalization of $13.98 billion, a price-to-earnings ratio of 37.02 and a beta of 0.33. Neurocrine Biosciences, Inc. has a one year low of $110.95 and a one year high of $157.98.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of institutional investors have recently made changes to their positions in NBIX. Commonwealth Equity Services LLC increased its holdings in shares of Neurocrine Biosciences by 7.0% in the 2nd quarter. Commonwealth Equity Services LLC now owns 14,916 shares of the company’s stock worth $2,054,000 after buying an additional 975 shares during the last quarter. Natixis Advisors LLC increased its holdings in shares of Neurocrine Biosciences by 11.1% in the 2nd quarter. Natixis Advisors LLC now owns 35,260 shares of the company’s stock worth $4,854,000 after buying an additional 3,531 shares during the last quarter. CIBC Asset Management Inc increased its holdings in shares of Neurocrine Biosciences by 4.7% in the 2nd quarter. CIBC Asset Management Inc now owns 3,400 shares of the company’s stock worth $468,000 after buying an additional 153 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Neurocrine Biosciences by 0.7% in the 2nd quarter. Rhumbline Advisers now owns 324,288 shares of the company’s stock worth $44,645,000 after buying an additional 2,181 shares during the last quarter. Finally, Belpointe Asset Management LLC increased its holdings in shares of Neurocrine Biosciences by 91.5% in the 2nd quarter. Belpointe Asset Management LLC now owns 8,113 shares of the company’s stock worth $1,117,000 after buying an additional 3,877 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on NBIX. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, December 20th. Wedbush reaffirmed an “outperform” rating and issued a $148.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Barclays lifted their price objective on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research report on Monday, December 23rd. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Five equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $166.29.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.